Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: Andrew H who wrote (1296)	6/18/1998 8:20:00 PM
From: BigDaddyMac	Read Replies (2) \| Respond to of 5402

Press release was just a little loose, <.Dress was the president and CEO of the only company to have obtained FDA approval for a synthetic blood product to date.> Sure this is true, but it is for dogs, kinda funny how they didn't print that information now isn't. people should stop talking about how much this company is worth, or going to be worth, that is pure hype and what has ruined alot of new companies. Right now this company is worth nothing, and it wont be for a long time, this is a long term hold, and very risky. If anybody thinks Baxter is going to come in and buy this company if it past even the first animal test phase, then i have some flea and tick medicine that was just approved for humans. :-) mitchell

To: Andrew H who wrote (1296)	6/18/1998 8:46:00 PM
From: macker	Read Replies (2) \| Respond to of 5402

the 30 mm is not just for animal trials but what is being committed to the project in bits and pieces as a long term umbrella package should they ever get to fda trial stages that require the big funding. but i agree with you, they will never get this product to market as i believe that they will get bought along with their technology well before they could get to market. batelle will draw a lot of attention to sgnc, i still dont believe this stock is a "get the product to market play", rather it is a somatogen style play of getting enough exposure to get the big boy to buy them out. they will never come remotely close to having enough money to manufacture or market such a product, like other prominent biotech's with a good technology, they are banking on a buyout. i think that this is one of the reasons that batelle is wanting a piece of the action so bad, they know that they have a diamond in the rough here. i appreciate your post here andrew, good insight. macker